CHF101.16
0.37% yesterday
SIX Swiss Exchange, Aug 29, 05:30 pm CET
ISIN
CH0012005267
Symbol
NOVN

Novartis Target price 2025 - Analyst rating & recommendation

Novartis Classifications & Recommendation:

Buy
42%
Hold
45%
Sell
13%

Novartis Price Target

Target Price CHF105.06
Price CHF101.16
Potential 3.86%
Number of Estimates 23
23 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF105.06. This is 3.86% higher than the current stock price. The highest price target is CHF126.00 24.56% , the lowest is CHF80.80 20.13% .
A rating was issued by 31 analysts: 13 Analysts recommend Novartis to buy, 14 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 3.86% . Most analysts recommend the Novartis stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion CHF 41.40 45.13
10.85% 9.01%
EBITDA Margin 31.96% 40.19%
14.24% 25.76%
Net Margin 23.09% 31.19%
27.46% 35.10%

24 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF45.1b . This is 2.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF48.7b 10.98% , the lowest is CHF41.4b 5.80% .

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF41.4b 10.85%
2025 CHF45.1b 9.01%
2026 CHF46.3b 2.49%
2027 CHF47.6b 3.01%
2028 CHF49.3b 3.42%
2029 CHF50.8b 3.00%
2030 CHF51.9b 2.31%
2031 CHF49.0b 5.57%
2032 CHF45.0b 8.20%

20 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF18.1b . This is 21.78% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF19.8b 33.03% , the lowest is CHF13.7b 8.17% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF13.2b 26.63%
2025 CHF18.1b 37.09%
2026 CHF18.5b 2.15%
2027 CHF19.2b 3.55%
2028 CHF20.9b 8.90%
2029 CHF21.8b 4.12%
2030 CHF23.7b 8.86%
2031 CHF18.6b 21.47%
2032 CHF16.4b 11.98%

EBITDA Margin

2024 31.96% 14.24%
2025 40.19% 25.76%
2026 40.06% 0.32%
2027 40.27% 0.52%
2028 42.40% 5.29%
2029 42.86% 1.08%
2030 45.61% 6.42%
2031 37.93% 16.84%
2032 36.36% 4.14%

25 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF14.1b . This is 28.77% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF15.0b 37.55% , the lowest is CHF12.6b 15.32% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF9.6b 19.59%
2025 CHF14.1b 47.24%
2026 CHF14.6b 3.96%
2027 CHF15.8b 7.89%
2028 CHF16.6b 5.22%
2029 CHF17.2b 3.76%
2030 CHF17.9b 4.10%
2031 CHF18.7b 3.96%
2032 CHF16.9b 9.36%

Net Margin

2024 23.09% 27.46%
2025 31.19% 35.10%
2026 31.63% 1.41%
2027 33.13% 4.74%
2028 33.70% 1.72%
2029 33.95% 0.74%
2030 34.55% 1.77%
2031 38.04% 10.10%
2032 37.55% 1.29%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share CHF 4.70 7.27
17.25% 54.68%
P/E 13.91
EV/Sales 4.74

25 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF7.27 . This is 30.52% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF7.77 39.50% , the lowest is CHF6.51 16.88% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF4.70 17.25%
2025 CHF7.27 54.68%
2026 CHF7.56 3.99%
2027 CHF8.15 7.80%
2028 CHF8.58 5.28%
2029 CHF8.90 3.73%
2030 CHF9.27 4.16%
2031 CHF9.63 3.88%
2032 CHF8.73 9.35%

P/E ratio

Current 18.16 18.12%
2025 13.91 23.41%
2026 13.38 3.81%
2027 12.41 7.25%
2028 11.79 5.00%
2029 11.36 3.65%
2030 10.92 3.87%
2031 10.50 3.85%
2032 11.58 10.29%

Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 4.74 and an P/S ratio of 4.28 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.87 17.04%
2025 4.74 2.74%
2026 4.62 2.43%
2027 4.49 2.93%
2028 4.34 3.31%
2029 4.21 2.91%
2030 4.12 2.26%
2031 4.36 5.90%
2032 4.75 8.93%

P/S ratio

Current 4.40 19.08%
2025 4.28 2.73%
2026 4.18 2.43%
2027 4.06 2.92%
2028 3.92 3.31%
2029 3.81 2.91%
2030 3.72 2.26%
2031 3.94 5.90%
2032 4.29 8.93%

Current Novartis Upgrades & Downgrades

Analyst Rating Action Date
JEFFERIES
Hold
Hold
Unchanged Jul 16 2025
TD COWEN
Hold
Hold
Unchanged Jul 16 2025
GUGGENHEIM SECURITIES LLC
Neutral
Neutral
Unchanged Jul 16 2025
ARGUS RESEARCH CORPORATION
Hold
Hold
Unchanged Jul 10 2025
BERENBERG
Hold
Hold
Unchanged Jul 08 2025
ROTHSCHILD & CO REDBURN
Sell
Sell
Unchanged Jul 03 2025
DAY BY DAY
Buy
Hold
Downgrade Jun 08 2025
Analyst Rating Date
Unchanged
JEFFERIES:
Hold
Hold
Jul 16 2025
Unchanged
TD COWEN:
Hold
Hold
Jul 16 2025
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
Neutral
Jul 16 2025
Unchanged
ARGUS RESEARCH CORPORATION:
Hold
Hold
Jul 10 2025
Unchanged
BERENBERG:
Hold
Hold
Jul 08 2025
Unchanged
ROTHSCHILD & CO REDBURN:
Sell
Sell
Jul 03 2025
Downgrade
DAY BY DAY:
Buy
Hold
Jun 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today